This site is intended for healthcare professionals
Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
The Committee on Safety of Medicines (CSM) has advised that the use of thioridazine should be restricted to the second line treatment of schizophrenia in adults:
The CSM advice notes that clinicians should re-evaluate their patients treated with thioridazine, in light of the new evidence. If thioridazine is discontinued then a gradual reduction in dose over one or two weeks is recommended.
The summary of product characteristics should be consulted before prescribing this drug.